Publications by authors named "Scott T Guenthner"
Background: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions.
Objective: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD).
Article Synopsis
- Current treatments for seborrheic dermatitis are not very effective or safe, prompting the need for new options.
- A clinical trial tested the safety and effectiveness of roflumilast foam, 0.3%, on adults with seborrheic dermatitis across 24 locations in the US and Canada.
- In the trial, 73.8% of patients using roflumilast foam achieved significant improvement in their condition after 8 weeks, compared to those using a placebo.
Introduction: Psoriasis is a chronic, immune-mediated skin disease that is associated with sex-related differences. Two double-blind, vehicle-controlled, phase 3 studies evaluated halobetasol propionate (HP) 0.01% lotion for the treatment of moderate-to-severe localized plaque psoriasis; pooled post hoc analyses investigated efficacy and safety in male and female subgroups.
View Article and Find Full Text PDFBackground: It is important to develop an understanding of what the public knows about skin cancer and what sun safety precautions they are taking. Research on the evaluation of skin cancer education targeting adults is minimal.
Aim: To assess the knowledge and behavior related to skin cancer and sun exposure, and to determine if an informal interaction between dermatologists and the public could promote skin cancer awareness and precautions.